Biohaven Pharmaceuticals在精准免疫治疗领域迈出关键一步。其首创的胞外蛋白降解剂BHV-1300，已正式启动针对格雷夫斯病的关键性三期临床试验。这标志着一种全新治疗模式的诞生。
BHV-1300作为首款进入临床后期的胞外蛋白降解疗法，旨在精确清除导致自身免疫性疾病的特定致病蛋白。其作用机制不同于传统药物，为格雷夫斯病患者带来了新的希望。
格雷夫斯病是一种常见的自身免疫性甲状腺疾病，目前治疗方案有限。BHV-1300的三期试验启动，是Biohaven在该领域研发实力的重要体现，也预示着精准免疫疗法可能迎来新的突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.